In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:

• Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules
• Available pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulations
• Current and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerations

Presenters:

Kelly Romo, PharmD, BCOP
Manager, Oncology Medical Drug Management and Customer Initiatives
Blue Cross Blue Shield Michigan
Detroit, Michigan

Shawna Kraft, PharmD, BCOP
Clinical Pharmacist, Specialist
Michigan Medicine, Rogel Cancer Center
Clinical Associate Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan

Resources:
Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic. 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, hear Allison Butts, PharmD, BCOP and Danielle Roman, PharmD, BCOP, share their insights on the best practices for incorporating antibody–drug conjugates (ADCs) into clinical practice including:

• An overview of ADC structure and mechanism of action
• A topline review of data supporting the current FDA-approved indications for ADCs targeting HER2 and TROP-2 across multiple tumor types
• An in-depth look at common and serious adverse events with each approved ADC along with an overview of management strategies

Editor’s note: On June 23, 2025, the FDA granted accelerated approval for a new indication for datopotamab deruxtecan, one of the antibody drug conjugates discussed in this podcast. Datopotamab deruxtecan is now also approved for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received previous EGFR-targeted therapy and platinum-based chemotherapy. 

Program faculty:

Allison Butts, PharmD, BCOP
Pharmacist Manager, Oncology
Clinical Pharmacist, Breast Oncology
UK HealthCare
Markey Cancer Center
Lexington, Kentucky

Danielle Roman, PharmD, BCOP
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Program page:
https://bit.ly/4lr7cT6

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Brett M. Elicker, MD, and David E. Griffith, MD, ATSF, FACCP, FRSM, discuss the pathophysiology of non–cystic fibrosis bronchiectasis (NCFBE), the patient burden, and best practices with diagnosing NCFBE, including:

• The vicious vortex of NCFBE (ie, airway dysfunction, inflammation, infection)
• Cough as the most significant symptom and burden
• Imaging bronchiectasis with classic and inflammatory findings
• Differentiating the causes of NCFBE to inform patient care

Presenters

Brett M. Elicker, MD
Professor of Clinical Radiology
Chief, Cardiothoracic Imaging Division
Department of Radiology & Biomedical Imaging
University of California, San Francisco
San Francisco, California

David E. Griffith, MD, ATSF, FACCP, FRSM
Professor of Medicine
Division of Mycobacterial and Respiratory Diseases
Department of Medicine
National Jewish Health
Denver, Colorado

Program page: 
https://bit.ly/4mZbYsm

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen in as Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss how to manage the multidisciplinary care of patients with systemic mastocytosis (SM) from both the allergy/immunology and pharmacy perspective, including:

• Strategies to better identify patients presenting with features of SM to facilitate timely diagnosis
• Current guideline-recommended treatment approaches
• Emerging data on new targeted agents for SM
• Pharmacist-led strategies to help patients achieve better outcomes (e.g., specialist referral, polypharmacy counseling, and anaphylaxis education)

Presenters
Jonathan A. Bernstein, MD
Professor of Medicine
Division of Rheumatology, Allergy and Immunology
Department of Internal Medicine
University of Cincinnati College of Medicine
Partner Advanced Allergy Services, LLC
Partner Bernstein Clinical Research Center, LLC
Cincinnati, Ohio

Ryan Haumschild, PharmD, MS, MBA, CPEL
Vice President of Pharmacy, Ambulatory
Emory Healthcare
Winship Cancer Institute
Atlanta, Georgia

Full link to program page:
https://bit.ly/3HcA8z2

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:

• Common comorbidities and complexities in managing patients with HR+/HER2- MBC
• Treatment landscape for patients with HR+/HER2- MBC
• Real-world studies in women with HR+/HER2- MBC
• Mitigation and management of drug interactions and multidisciplinary team coordination treatment selection
• Patient goals and coordinating with multidisciplinary team to maximize quality of life

Link to full program:
https://bit.ly/4jCQe38

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Alexa Basilio, PharmD, BCOP and Jessica Davis, PharmD, BCOP, CPP discuss immune-related adverse events and toxicities among patients using immune checkpoint inhibitors. This overview will include discussion about: 

• How and when to monitor and treat mild vs severe immune-related toxicities
• The art of balancing and tapering low-dose and high-dose corticosteroids
• Differentiating between immune-related and chemotherapy- or targeted therapy–associated adverse events for optimal management approaches
• Involvement of multidisciplinary teams early during treatment to prevent immune-related adverse events
• Importance of educating patients, caregivers, and providers on immune-related toxicities

Presenters: 

Alexa Basilio, PharmD, BCOP
University of Florida College of Pharmacy 
Oncology Pharmacy Specialist 
McKesson, The US Oncology Network
Tampa, Florida 

Jessica Davis, PharmD, BCOP, CPP 
Levine Cancer Institute
Clinical Pharmacist Coordinator, Adult Hematology/Oncology
Atrium Health Levine Center
Charlotte, North Carolina 

Link to full program: 
https://bit.ly/3We4HJy

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:

• Engage key stakeholders in the provision of HBV care​
• Provide HBV management resources to support PCPs who are doing screening​
• Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBV

Presenters:

Su Wang, MD, MPH, FACP
Medical Director
Center for Asian Health and Viral Hepatitis Programs
Cooperman Barnabas Medical Center
RWJBarnabas-Rutgers Medical Group
Associate Member
Health Care Policy and Aging Research
The Rutgers Institute for Health
Senior Advisor
Global Health, Hepatitis B Foundation
Florham Park, New Jersey

Richard R. Andrews, MD, MPH
President, Houston Viral Hepatitis Task Force
Former Co-Chair, National Task Force on Hepatitis B
Board-Certified Family Medicine
Addiction Medicine Physician
Houston, Texas

Ruth Brogden, MPH
Patient Advocate

Amy S. Tang, MD
Former Co-Chair, National Task Force on Hepatitis B
Director of Immigrant Health
North East Medical Services
San Francisco, California

Link to full program: 
https://bit.ly/3TuqFHI

Link to the slides:
https://bit.ly/44hXpHu

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:

• Patient subgroups to consider for treatment outside guideline criteria
• Adverse event and cost-effectiveness considerations
• Integration of patient perspectives in wider treatment

Presenters:

Mark S. Sulkowski, MD, FIDSA, FAASLD
Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Jacki Chen, PhD
Patient Advocate 

Link to full program: 
https://bit.ly/3TuqFHI

Link to the slides:
https://bit.ly/4a60GM4

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:

• Updated CDC recommendations for one-time universal screening for HBV
• Addressing patient-, provider-, and system-level barriers to universal HBV screening
• Best practices for implementation of HDV screening

Presenters:

Douglas Dieterich, MD
Director, Institute for Liver Medicine

Professor of Medicine

Division of Liver Diseases

Mount Sinai School of Medicine

New York, New York

Camilla S. Graham, MD, MPH
Co-Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Robert Wong, MD, MS 
Clinical Associate Professor
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Palo Alto, California

Link to full program:
https://bit.ly/3TuqFHI

Link to the slides: 
https://bit.ly/4atS42z

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:

• Burden of CRE infections in the United States
• Mechanisms of resistance
• Changing epidemiology
• Use of rapid diagnostic tests
• IDSA guidance recommendations, including supporting data
• Approach to designing treatment regimens, including weighing patient- and infection-related factors

Faculty:

Julie Ann Justo, PharmD, MS, FIDSA, BCPS
Clinical Pharmacist Lead – Infectious Diseases
Inpatient Pharmacy
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire

Link to full program: 
https://bit.ly/41a8Mj0

Link to accompanying ClinicalThought commentary:
https://bit.ly/4865T57

Link to downloadable infographic: 
https://bit.ly/3t7NpT2

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.